Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Expects Revenue From Molecular Dx to Be Between $23M and $26M in 2005

NEW YORK, Nov. 11 (GenomeWeb News) - Third Wave Technologies expects revenues from clinical molecular diagnostic products to expand to between $23 million and $26 million in 2005, the company said today.

The company said the revenue will be "driven chiefly by the company's core genetics, cystic fibrosis and HCV genotyping reagents."

 

The company this morning scheduled a conference call to detail expansion of its molecular diagnostic product development efforts to move the company past the core SNP detection technology products market it serves with its Invader-brand chemistry.

 

Third Wave generated $36.3 million in 2003. The company does not break down revenues for its molecular diagnostics business.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.